2021
Executive Summary Screening for Lung Cancer: Chest Guideline and Expert Panel Report
Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, Wiener RS, Detterbeck FC. Executive Summary Screening for Lung Cancer: Chest Guideline and Expert Panel Report. CHEST Journal 2021, 160: 1959-1980. PMID: 34270965, PMCID: PMC8727851, DOI: 10.1016/j.chest.2021.07.003.Peer-Reviewed Original ResearchConceptsNational Lung Screening TrialLow-dose chest CTLung cancerCT screeningChest CTClinical questionsLow-dose CT screeningEvidence baseLow-dose chest CT screeningAdditional clinical questionsScreen-detected findingsScreening-eligible individualsGrading of RecommendationsChest CT screeningStandard of careImportant clinical questionsSystematic literature reviewExpert Panel ReportLow-dose CTCHEST GuidelineCessation interventionsCochrane LibraryGuideline publicationLiterature reviewConsensus statement
2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2018
Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement
Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS. Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2018, 198: e3-e13. PMID: 30004250, DOI: 10.1164/rccm.201805-0986st.Peer-Reviewed Original ResearchConceptsLung cancer screeningRisk of deathPatient selectionChronic illnessCancer screeningLung cancerOfficial American Thoracic Society Research StatementHarms of LCSImplementation of LCSScreen-detected lung cancersChronic obstructive pulmonary diseaseRisk of comorbiditiesObstructive pulmonary diseaseEffect of comorbidityLung cancer deathsTreatment-related harmsLung cancer riskBalance of benefitsPulmonary diseaseCancer deathBaseline riskCancer riskComorbiditiesHealthy individualsInternational clinicians
2017
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?
Detterbeck FC. The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Journal Of Thoracic And Cardiovascular Surgery 2017, 155: 356-359. PMID: 29061464, DOI: 10.1016/j.jtcvs.2017.08.138.Peer-Reviewed Original ResearchIndications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT
Gao SJ, Kim AW, Puchalski JT, Bramley K, Detterbeck FC, Boffa DJ, Decker RH. Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT. Lung Cancer 2017, 109: 36-41. PMID: 28577947, DOI: 10.1016/j.lungcan.2017.04.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungClinical Decision-MakingDiagnostic ImagingFemaleHumansLung NeoplasmsMaleMediastinumMiddle AgedNeoplasm MetastasisNeoplasm StagingPatient SelectionPositron Emission Tomography Computed TomographyPractice Guidelines as TopicRetrospective StudiesConceptsOccult N2 diseaseOccult N2 metastasesGround-glass componentInvasive mediastinal stagingCurative-intent therapyT2 tumorsN2 metastasisPET-CTInvasive stagingN2 diseaseT1 tumorsNegative predictive valueMediastinal stagingEarly non-small cell lung cancerExact testPredictive valueSolid tumorsNon-small cell lung cancerClinical stage I NSCLCN2 lymph nodesNode-negative NSCLCOccult nodal involvementPure-solid tumorsStage I NSCLCT1-2N0 disease
2013
Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e369s-e399s. PMID: 23649447, DOI: 10.1378/chest.12-2362.Peer-Reviewed Original ResearchConceptsSecond primary lung cancerChest wall involvementPrimary lung cancerLung cancerSurgical resectionPancoast tumorWall involvementAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesMetachronous second primary lung cancerEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisNon-small cell lung cancerLonger disease-free intervalCell lung cancer diagnosisIpsilateral different lobeMediastinal node involvementN2 nodal diseaseSpecial clinical casesThoracic Oncology NetworkAggressive surgical approachDisease-free intervalPrimary surgical resectionExperienced multidisciplinary teamLarge prospective studiesTreatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC, Arenberg DA. Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 2013, 143: e314s-e340s. PMID: 23649445, DOI: 10.1378/chest.12-2360.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLung cancerDefinitive chemoradiationNeoadjuvant therapyStage IIIARandomized trialsPractice guidelinesAmerican CollegeChest Physicians Evidence-Based Clinical Practice GuidelinesEvidence-based clinical practice guidelinesNon-small cell lung cancer diagnosisLow perioperative mortality ratePlatinum-based adjuvant chemotherapyStage IIIA lung cancerStage III lung cancerCell lung cancer diagnosisIIIA lung cancerMicroscopic nodal metastasesProphylactic cranial radiationChest Physicians guidelinesPerioperative mortality rateCell lung cancerClinical practice guidelinesStrength of recommendationsLung cancer diagnosis
2012
Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry
Ahmad U, Wang Z, Bryant AS, Kim AW, Kukreja J, Mason DP, Bermudez CA, Detterbeck FC, Boffa DJ. Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry. The Annals Of Thoracic Surgery 2012, 94: 935-941. PMID: 22835555, DOI: 10.1016/j.athoracsur.2012.04.069.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Bronchiolo-AlveolarAdultAnalysis of VarianceCause of DeathDisease-Free SurvivalFemaleGraft RejectionGraft SurvivalHospital MortalityHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsLung TransplantationMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPatient SelectionPreoperative CarePrognosisProportional Hazards ModelsRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTissue and Organ ProcurementTreatment OutcomeConceptsLung transplantationBronchoalveolar carcinomaLung transplantUnited NetworkLung cancerDouble lung transplantOrgan Sharing databaseOrgan Sharing registrySubgroup of patientsMaximum survival advantageBAC patientsSecond percentExpiratory volumeMedian survivalTransplantation cohortSharing databasePoor prognosisPure adenocarcinomaPathology reportsInvasive tumorsSurvival advantageExtended survivalTransplantationPatientsTransplantCurrent Status of Lung Cancer Screening
Ahmad U, Detterbeck FC. Current Status of Lung Cancer Screening. Seminars In Thoracic And Cardiovascular Surgery 2012, 24: 27-36. PMID: 22643659, DOI: 10.1053/j.semtcvs.2012.01.014.Peer-Reviewed Original Research
2009
What is Quality and Does it Matter?
Detterbeck F. What is Quality and Does it Matter? Journal Of Thoracic Oncology 2009, 4: 279-280. PMID: 19247081, DOI: 10.1097/jto.0b013e3181989be5.Peer-Reviewed Original Research
2006
Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database
Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. Journal Of Clinical Oncology 2006, 24: 2998-3006. PMID: 16769986, DOI: 10.1200/jco.2005.04.6110.Peer-Reviewed Original ResearchConceptsT3-4 tumour stageUse of PORTN2 nodal diseaseEnd Results (SEER) databasePostoperative radiotherapyCell lung cancerLymph nodesNodal diseaseResults databaseTumor stageLung cancerNode stageStage IIHigher American Joint CommitteeAdvanced node stageAmerican Joint CommitteePopulation-based cohortLarger tumor sizeMedian followPerioperative mortalityMale sexTumor sizeSubset analysisCancer stageInclusion criteria
2003
A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors
Poole ME, Bernard SA, Churchel MA, Weissler MC, Calvo B, Cance W, Ollila D, Koruda M, Behrns K, Detterbeck FC. A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors. Cancer Investigation 2003, 21: 350-354. PMID: 12901280, DOI: 10.1081/cnv-120018225.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityDose of docetaxelPhase IDay 1Solid tumorsAdvanced-stage solid tumorsSignificant nonhematologic toxicityPhase II studyRefractory solid tumorsPhase I studiesM2 i.Nonhematologic toxicityStable diseaseStarting doseII studyPartial responseHypersensitivity reactionsI studiesGastric cancerPrimary siteGemcitabinePatientsDocetaxelDoseConstant dose